We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -1.85% | 13.25 | 13.00 | 13.50 | 13.50 | 13.25 | 13.50 | 696,978 | 10:19:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.86M | -0.0063 | -21.03 | 125.26M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/11/2024 14:41 | Reform chairman: Council victory shows we’ll be ‘formidable force’ Reform UK gained a ward from Labour in a Cabinet minister’s constituency at a council by-election last night. Nigel Farage’s party won in Bilston North which is located in the seat of Pat McFadden, the Chancellor of the Duchy of Lancaster. Reform won 34.8 per cent of the vote as it contested the seat for the first time, while Labour’s vote share more than halved to 25.1 per cent and the Greens came third with 23.4 per cent. Gathering Pace | inanaco | |
01/11/2024 14:23 | i assume you have cut your losses here then Ivy 😌 | inanaco | |
01/11/2024 13:45 | Yep Loz some just cannot grasp the simple concepts that you espouse. Same with shares remember Tosh and his freebie shares gotten through astute buying and selling unlike some who will never have the wit ir wisdom to see the folly of how they operate. Nana born and bred to be an eternal Loser. | ivyspivey | |
01/11/2024 13:40 | Interesting company. IO112 is an immune modulatory cancer therapy under preclinical development to target arginase-1-expressin | marcusl2 | |
01/11/2024 12:54 | "your skint" - Was wondering, Why, following education given to my generation, the powers that be deemed it a 'good idea' to,as WE ALL observe on a near daily basis, to drastically lower the level of education available ??? Have just spent a few hours in the sun 28 C, cutting to length, fallen branches and logs we have collected locally this summer. Strangely,FREE firewood seems to burn much hotter A bit like 'shares' give much more satisfaction when, given a little nous they CAN be picked-up for FREE Cost FREE ergo RISK FREE Not everyone, it seems, is willing to understand that. | the real lozan | |
01/11/2024 12:38 | any way cheer up all our deals are in $ not the sinking pound | inanaco | |
01/11/2024 12:34 | ‘Saying the word “growth” 31 times won’t make it happen’ “A nation trying to tax itself into prosperity is like a man standing in a bucket trying to lift himself up by the handle.” It’s a gag Winston Churchill used often – and it hasn’t worn with age, writes Liam Halligan. | inanaco | |
01/11/2024 12:27 | they have a lot more detail on market size | inanaco | |
01/11/2024 12:19 | one other point to do a real comparison you need 100% patient treated so ISCB1 data | inanaco | |
01/11/2024 12:14 | ""did not meet the criteria to declare superiority of ORR."" scancell is declaring superiority of ORR the null response point | inanaco | |
01/11/2024 12:12 | The per-protocol interim analysis was performed one year after 225 patients were randomized in the trial. The interim efficacy analysis was intentionally set with a high statistical bar (p≤0.005), and based on the analysis, the IDMC determined that the data did not meet the criteria to declare superiority of ORR. The trial was designed to preserve most of the statistical alpha for the trial’s primary endpoint of PFS. The PFS analysis is event-driven and will be conducted when 226 events (disease progression or death) have been reported in the trial with independent central review. With 407 patients randomized, the trial is powered at 89% to detect a 35% reduction in the risk of an event. “To date, none of the approved immunotherapeutic combinations for the treatment of advanced melanoma demonstrated statistical significance in ORR in large Phase 3 trials; nevertheless, these trials achieved statistical significance on PFS,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “Based on the 25.5 months median PFS we observed in the Phase 1/2 trial of IO102-IO103 in combination with a PD-1 inhibitor in advanced melanoma, with no added significant systemic toxicity than that typically seen with anti-PD-1 monotherapy, we remain optimistic about meeting the primary endpoint of PFS, projected to occur in the first half of 2025.” | inanaco | |
01/11/2024 12:03 | what i am interested in ..... can we win on toxicity long term safety PFS and ORR with OS to follow so far the answer is Yes in 13 patients | inanaco | |
01/11/2024 12:00 | its so complex ...... but nature gave t cells an on off switch and we mess with it .... by blocking they target the switch ... the ligand as its over expressed however we do have natural t cells that can target the ligand ..... as a background how that all fits together ... ask a real expert | inanaco | |
01/11/2024 11:48 | well its a different approach to a cancer vaccine ... because you are vaccinating against the cancers ability to cloak problem with that its systemic which is why they use the words "over expressed" so look at toxicity first ..... how many drop out of treatment how many grade 3 or 4 and what is the effect long term of memory t cells that can attack self | inanaco | |
01/11/2024 11:39 | A Scancell post. Give your opinion Inan. Especially IO Biotech IO102-IO103 is administered subcutaneously (SC) IO102-IO103 is under investigation with nivolumab-relatlimab (anti-PD-1 mAb + anti-LAG-3 mAb) or pembrolizumab (anti-PD-1 mAb) | marcusl2 | |
01/11/2024 11:38 | its the markets that will bring down this Gov ..... and i suspect very quickly Investors are increasing bets that pound will plunge, says Barclays Traders are building up short positions against the pound following the Budget, according to Barclays. Hedge funds and assets managers are increasing their bets that the value of the pound will decline in reaction to the Chancellor’s tax raising plans. Barclays said that investors are now holding more short bets than long positions against the currency, where traders buy sterling in anticipation of its value rising. Investors now hold more short bets against the pound that long bets following the Budget, according to Barclays. Mimi Rushton, global head of currency distribution at Barclays, told Bloomberg: “At the margin, we’ve seen people selling pounds.” The pound has traded flat against the dollar since markets opened today, hovering around its lowest level since August. | inanaco | |
01/11/2024 11:34 | well MT .... on the basis that i know what i am talking about I bought more !! funny thing is ... You know whats coming !! you don't have to understand the science ... you only have to understand one thing Can T cells kill cancer are Scancells little killers good enough thats it then monitor all the replies to this post which one failed Scb1 or Keytruda as simple as it sounds that all it is ..... | inanaco | |
01/11/2024 11:23 | what about a lecture on the "impact of the budget on wealth AIM and ISA shares" or the effects of CGT increases ..... how your risk reward has changed strange isn't it how all my posts before the budget about politics suddenly ... Affect you directly !! | inanaco | |
01/11/2024 11:22 | I've given up bothering, Nigel. I may not have much to say that is scientifically illuminating.....but at least people were never fooled into thinking otherwise. Markets, however, will soon be a bit more important.... | markingtime | |
01/11/2024 11:17 | waiting for you Nigel ..... thought you might give us a science lecture | inanaco | |
01/11/2024 11:15 | you always seem to be on the wrong side of the political divide Ivy Brexit ........ staunch remainer or Liberal Election .... Corbyn ... you backed him with a PLO flag Election Starmer ............. 120 days of misery i jumped ship as the conservatives went left .... seems my steering gear is in tact ... soon know about my stock picking | inanaco | |
01/11/2024 11:14 | Off we go again. Loads of posts with nothing at all to do with scancell. Brain dead stuff also. | nigelpm | |
01/11/2024 11:11 | even Moody people give opinions .... Britain faces years of ‘muted’ growth, warns Moody’s Britain faces years of “muted” growth and higher borrowing costs after Rachel Reeves’ maiden Budget, Moody’s has warned. In a note to investors, the leading credit rating agency warned the Chancellor’s decisions will put government debt “on a slow upward trajectory” and cast doubt on the credibility of new debt rules meant to reassure financial markets. Moody’s also warned that higher spending on infrastructure would only boost growth if ministers successfully tackled issues that have dogged the UK economy for years, such as the worklessness crisis and long planning delays. The agency’s note, published this morning, warned that Ms Reeves’ debt-fuelled spending binge was the “most aggressive” since furlough and other Covid-era support measures. | inanaco | |
01/11/2024 11:09 | you need to find The Guardian or the Mirror BB's Ivy ... you can sprout off your "Moral" codes and what ever else indoctrinated Grubby socialist do ... the "deception" training camps ....you never know Lord Ali might dress you | inanaco |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions